There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agilent (A) and Protagonist Therapeutics (PTGX) with bullish sentiments.
Agilent (A)
In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Agilent, with a price target of $95.00. The company’s shares closed last Thursday at $80.75.
According to TipRanks.com, Souda is a 5-star analyst with an average return of 21.0% and a 69.4% success rate. Souda covers the Healthcare sector, focusing on stocks such as Castle Biosciences, Guardant Health, and Exact Sciences.
Currently, the analyst consensus on Agilent is a Moderate Buy with an average price target of $82.67.
See today’s analyst top recommended stocks >>
Protagonist Therapeutics (PTGX)
Leerink Partners analyst Joseph Schwartz maintained a Buy rating on Protagonist Therapeutics today and set a price target of $30.00. The company’s shares closed last Thursday at $16.00, close to its 52-week high of $17.33.
According to TipRanks.com, Schwartz is a 5-star analyst with an average return of 18.6% and a 53.4% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals, BioMarin Pharmaceutical, and Ascendis Pharma.
Currently, the analyst consensus on Protagonist Therapeutics is a Moderate Buy with an average price target of $29.00, which is an 86.0% upside from current levels. In a report issued on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $23.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
